Clinical Brief: Update on Antiplatelet and Antithrombotic Therapy in the Cardiometabolic Patient
Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD and PAD compared to patients with these conditions and no concomitant diabetes. As such, current antithrombotic strategies to prevent adverse events in these high-risk patients may not be adequate, and several recently-completed and ongoing clinical trials are evaluating the efficacy and safety of additional approaches, including the use of more aggressive and specific antithrombotic agents in this setting. Clinicians need to be aware of the results of these trials and their clinical practice implications in order to improve patient outcomes. This Clinical Brief is a short, to-the-point, online enduring activity covering key points, clinical pearls, and expert perspectives discussed throughout the CMHC West 2020 Live Online session.
This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.
After completing this activity, the participant should be better able to:
- Define the association between diabetes and increased thrombotic risk and adverse events in patients with CAD and PAD.
- Interpret the results of recently concluded clinical trials about the efficacy and safety of novel antithrombotic approaches in patients with diabetes and concomitant CAD and PAD to inform treatment decisions.
Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC
Mount Sinai Professor Of Cardiovascular Clinical Research and Outcomes
Professor of Medicine (Cardiology), and Population Health Science and Policy
Director of Interventional Cardiovascular Research and Clinical Trials,
Icahn School of Medicine at Mount Sinai,
New York, NY, USA
Dr. Mehran reports institutional research grants from Abbott Laboratories, Abiomed, Applied Therapeutics, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, OrbusNeich; consultant fees from Abbott Laboratories, Boston Scientific, Janssen Scientific Affairs, Medscape/WebMD, Medtelligence (Janssen Scientific Affairs), Roivant Sciences, Sanofi, Siemens Medical Solutions; consultant fees paid to the institution from Abbott Laboratories, Bristol-Myers Squibb; advisory board, funding paid to the institution from Spectranetics/Philips/Volcano Corp; consultant (spouse) from Abiomed, The Medicines Company, Merck; Equity <1% from Claret Medical, Elixir Medical; DSMB Membership fees paid to the institution from Watermark Research Partners; consulting (no fee) from Idorsia Pharmaceuticals Ltd., Regeneron Pharmaceuticals. Associate Editor for ACC, AMA.
This activity is supported by an educational grant from AstraZeneca.
JOINTLY PROVIDED BY
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Cardiometabolic Health Congress. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Category 1 CreditTM Designation Statement
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
ANCC Contact Hour
The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
0.75 contact hours may be earned for successful completion of this activity.
Continuing Pharmacy Education
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is assigned ACPE Universal Activity #0797-9999-20-122-H01-P. This program is designated for up to 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dietician Continuing Education
This program offers 0.75 CPEUs for dieticians.
ACCREDITED PROVIDER DISCLOSURE
Annenberg Center for the Health Sciences at Eisenhower staff involved in this activity have no relevant commercial relationships to disclose.
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
CONFLICT OF INTEREST DISCLOSURE POLICY
Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to Annenberg Center for Health Sciences at Eisenhower policy. Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period December 1, 2020 through December 1, 2021, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be emailed. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.annenberg.net.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 CDE
- 0.75 Participation
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.